Related Experiment Videos
Polyamine depletion therapy in prostate cancer
B H Devens1, R S Weeks, M R Burns
1Oridigm Corporation, Seattle, WA, USA.
Prostate Cancer and Prostatic Diseases
|December 24, 2002
Summary
Combining polyamine synthesis inhibition with transport blockade effectively slowed prostate cancer growth. This dual approach reduced tumor polyamine levels, offering a promising therapeutic strategy for prostate tumors.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Polyamines are crucial for prostate cell function and are elevated in prostate cancer.
- Previous attempts to target polyamine synthesis alone were limited by cellular uptake mechanisms.
Purpose of the Study:
- To investigate the efficacy of a combination therapy targeting both polyamine synthesis and transport in prostate cancer.
- To evaluate the impact of this combination on tumor growth and polyamine levels.
Main Methods:
- Utilized DFMO (alpha-difluoromethylornithine) to inhibit ornithine decarboxylase, a key enzyme in polyamine synthesis.
- Employed ORI 1202, a novel inhibitor of polyamine transport into cells.
- Tested the combination on human prostate cancer cell lines (PC-3, LNCaP.FGC, DU145) in vitro and PC-3 xenografts in vivo.
Main Results:
- The combination therapy significantly slowed the growth of PC-3, LNCaP.FGC, and DU145 prostate cancer cell lines in vitro.
- Significant growth inhibition of PC-3 xenografts in nude mice was observed.
- Tumor polyamine levels were reduced compared to control groups.
Conclusions:
- Combination blockade of polyamine synthesis and transport is an effective strategy against prostate cancer.
- This approach demonstrates potential as a non-toxic therapeutic option for prostate tumors, even with high extracellular polyamines.